DNA

Acasti Pharma Reports Third Quarter 2023 Operational Results

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc.…

1 year ago

Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update

First subject enrolled into the OPMD clinical development programHAYWARD, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:…

1 year ago

Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split

DOYLESTOWN, Pa., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing…

1 year ago

Segra International Analytical Testing License

VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Segra International Corp. (“Segra”), an agriculture technology company is pleased to…

1 year ago

By The Bay Health CEO Announces Retirement

Efforts to identify new executive underway Kitty Whitaker Kitty Whitaker, retiring CEO of By the Bay HealthLARKSPUR, Calif., Feb. 06,…

1 year ago

Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader…

1 year ago

Genetic Technologies Announces $5 Million Registered Direct Offering

MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global…

1 year ago

GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

MELBOURNE, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader…

1 year ago

Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging…

1 year ago

Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the…

1 year ago